APA (7th ed.) Citation

ML, Ţ., L, P., A, B., C, P., T, B., J, S. O. S., . . . V, L. (2024). Design, synthesis and preliminary biological evaluation of rivastigmine-INDY hybrids as multitarget ligands against Alzheimer's disease by targeting butyrylcholinesterase and DYRK1A/CLK1 kinases. RSC medicinal chemistry, 15(3), 963. https://doi.org/10.1039/d3md00708a

Chicago Style (17th ed.) Citation

ML, Ţînţaş, Peauger L, Barré A, Papamicaël C, Besson T, Sopkovà-de Oliveira Santos J, Gembus V, and Levacher V. "Design, Synthesis and Preliminary Biological Evaluation of Rivastigmine-INDY Hybrids as Multitarget Ligands Against Alzheimer's Disease by Targeting Butyrylcholinesterase and DYRK1A/CLK1 Kinases." RSC Medicinal Chemistry 15, no. 3 (2024): 963. https://doi.org/10.1039/d3md00708a.

MLA (9th ed.) Citation

ML, Ţînţaş, et al. "Design, Synthesis and Preliminary Biological Evaluation of Rivastigmine-INDY Hybrids as Multitarget Ligands Against Alzheimer's Disease by Targeting Butyrylcholinesterase and DYRK1A/CLK1 Kinases." RSC Medicinal Chemistry, vol. 15, no. 3, 2024, p. 963, https://doi.org/10.1039/d3md00708a.